Shuffling the chairs at the top of the totem poll for Alliqua, Inc. (ALQA) has proven to be beneficial for shareholders who got in dureing election week. Following the path many successful biotechs have carved in recent months, ALQA stock has been slowly climbing up the charts since James Sapirstein was appointed the Company’s CEO and a Class I member of the Board. With plans of expanding their SilverSeal® products as well as other future clinical developments, this is one sleeper stock with a 328% potential upside.
Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
ALQA Stock Chart
Market Cap: 15.95M
Close: 0.068, up 0.003 (4.62%)
Volume: 464,585
Dollar Volume: $31,403
High: 0.07
Low: 0.063
Trades: 57
Average Trade Size: 8,150
Authorized: 500,000,000
Issued and Outstanding: 234,502,434
Looking for Hot Penny Stocks?
Click here and get Alerts on the Best Penny Stocks FREE
Friday’s trading session ended rather flat with any involvement pretty much ending at the lunch break versus the excitement that began the week when shares in Alliqua shot up to as high as 0.09. Yet the creation of a new position, Vice President, Medical Affairs, and appointing Joseph Laudano, Pharm.D to it is a major move to getting the Company’s FDA approved SilverSeal® hydrogels into the market. Capturing the marketplace in the medical marketplace for the management of open wounds is a requirement, not an option, since the biopharmaceutical company desperately needs some band-aids for their declining revenues.
For the three months ended June 30, 2012, three major customers accounted for approximately 92% of revenue, with each customer individually accounting for 66%, 15%, and 11% of total revenue. Not good when revenues were just $258,869 for the three months ended June 30, 2012, compared to $848,228 for the same period in 2011, and $454,470 for the six months ended June 30, 2012, compared to $1,251,620 for the same period in 2011. Unless Alliqua can avoid dependency on any one particular customer, these drops in revenues are going to continue to be a huge disappointments for shareholders.
With some promising updates and a better than expected 10-Q for the three months ended September 30, 2012, ALQA stock holders would like to be optimistic about seeing the 0.30 share price experienced in May, 2011.
About ALQA Stock
Alliqua, Inc. is a biomedical company that does business through the following wholly owned subsidiaries:
● AquaMed, through which the Company develops, manufactures and markets high water content, electron beam cross-linked, aqueous polymerhydrogels (“gels”) used for wound care, medical diagnostics, transdermal drug delivery and cosmetics.
● Alliqua Biomedical, Inc., through which the Company focuses on the development of proprietary products for wound care dressings and a core transdermal delivery technology platform designed to deliver drugs and other beneficial ingredients through the skin.
● HepaLife Biosystems, Inc., through which the Company holds legacy technology called HepaMate™.
Last 5 Trading Sessions:
| Date | Last | Change | % Change | Volume |
| 11/16/12 | 0.0680 | +0.0030 | +4.62% | 464,500 |
| 11/15/12 | 0.0650 | +0.0090 | +16.07% | 470,500 |
| 11/14/12 | 0.0560 | -0.0020 | -3.45% | 552,100 |
| 11/13/12 | 0.0580 | unch | unch | 1,078,600 |
| 11/12/12 | 0.0580 | +0.0040 | +7.41% | 1,785,700 |
Click here to view the SEC filings for ALQA.
Bottom Line: AMBS was a tremendous success and ALQA looks to follow the path of previous biotech penny stocks. Although revenues are down compared to last year, ALQA stock has been moving off its near year to date low since October began and, without some stellar announcements, is likely to have hit a ceiling for the time being. Nevertheless, biotechs can bust out like caged gorillas when news breaks so keep a close eye on it moving forward for cheapies.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareNOV
